Skip to main content

Fetal Hypoxia

1
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
Fetal Oxygenation MeasurementsPhase 11 trial
Active Trials
NCT06405984Completed35Est. Oct 2025
Raydiant Oximetry
Raydiant OximetryCA - San Ramon
4 programs
Dual fetal oxygen sensorsN/A1 trial
Fetal Pulse OximeteryN/A1 trial
GEN 3 Monitoring of FetusN/A1 trial
Fetal Oxygenation MeasurementsPHASE_1
Active Trials
NCT05147584Terminated31Est. Nov 2023
NCT07296419Recruiting15Est. Apr 2026
NCT04876846Completed9Est. Nov 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Human BioSciencesFetal Oxygenation Measurements
Raydiant OximetryFetal Pulse Oximetery
Raydiant OximetryDual fetal oxygen sensors
Raydiant OximetryGEN 3 Monitoring of Fetus

Clinical Trials (4)

Total enrollment: 90 patients across 4 trials

NCT06405984Human BioSciencesFetal Oxygenation Measurements

Trans-Abdominal Fetal Pulse Oximetry - EFS-IDE

Start: Apr 2024Est. completion: Oct 202535 patients
Phase 1Completed
NCT07296419Raydiant OximetryFetal Pulse Oximetery

Dual System Study: Transvaginal Fetal Pulse Oximetry Measurement Systems

Start: Dec 2025Est. completion: Apr 202615 patients
N/ARecruiting
NCT05147584Raydiant OximetryDual fetal oxygen sensors

Trans-abdominal Fetal Pulse Oximetry

Start: Jul 2022Est. completion: Nov 202331 patients
N/ATerminated
NCT04876846Raydiant OximetryGEN 3 Monitoring of Fetus

Trans-abdominal Fetal Pulse Oximetry; Tissue Light Scattering and Signal Integrity

Start: Apr 2021Est. completion: Nov 20259 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 90 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.